May 7, 2019 New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers
May 1, 2019 Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Apr 4, 2019 Syros Announces Proposed Concurrent Public Offerings of Common Stock with Warrants to Purchase Common Stock and Preferred Stock with Warrants to Purchase Common Stock
